Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue
+5.86%
EPS
−95.8%
Free cash flow
−21.4%
Total debt
−9.16%

Quarter to September 2026, against a year earlier

275.17 2.85 +1.05%
Market cap
$655.6B
P/E
41.3×
Fwd P/E
40.0×
Dividend yield
1.94%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
5 6 4 4

+8 more TTM periods

ROE
20.02% 25.74% 26.42% 35.03%
ROA
8.25% 10.67% 10.66% 14.13%
ROIC
11.07% 15.51% 16.13% 20.19%
Return on Tangible Assets
64.39% 73.92% 85.09% 108.66%
Average Days of Receivables
69.77 70.99 67.12 66.57
Free Cash Flow per Share
8.71 9.44 7.58 8.48
Free Cash Flow
20,990.00 22,724.00 18,254.00 20,418.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026